Physician profile
Robert E Cohen
NPI 1245267905
$9,184.54
in general payments reported to CMS, 2019-2025
28 companies · $3,089 in 2025
The $3,089 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $77.64 · 2022: $998 · 2023: $1,831 · 2024: $1,865 · 2025: $3,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,686 · Education: $99.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,685.70 |
| Education | $99.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,486.01 | 2022-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,317.35 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,034.03 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Neurocrine Biosciences, INC. | $787.90 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $684.91 | 2019-2025 | Trintellix |
| Alkermes, INC. | $645.37 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $515.57 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $513.87 | 2022-2025 | Caplyta |
| Lundbeck LLC | $336.48 | 2019-2025 | Rexulti |
| Merz North America, INC. | $220.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $212.80 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $206.67 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $190.25 | 2019-2025 | Spravato, Invega Sustenna |
| Allergan, INC. | $180.86 | 2019 | |
| Almatica Pharma LLC | $159.89 | 2022-2025 | Loreev Xr, Sertraline Hcl |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $138.92 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Janssen Scientific Affairs, LLC | $100.61 | 2023 | Spravato |
| Merck Sharp & Dohme LLC | $83.32 | 2022-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $75.60 | 2019 | |
| Indivior INC. | $60.13 | 2024 | Sublocade |
| Supernus Pharmaceuticals, INC. | $45.01 | 2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $44.74 | 2019 | |
| Neuronetics, INC. | $44.23 | 2024 | Neurostar Tms Therapy System |
| Idorsia Pharmaceuticals US INC | $25.82 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $23.85 | 2025 | Xelstrym, Secuado |
| Braeburn INC. | $18.66 | 2024 | Brixadi |
| Tris Pharma INC | $17.08 | 2023 | Dyanavel Xr |
| Shire North American Group INC | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.